Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Hits Estimates

Savara (NASDAQ:SVRA) announced its quarterly earnings results on Tuesday. The company reported ($0.11) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.11), Zacks reports.

Savara Trading Down 9.9 %

Shares of SVRA stock traded down $0.38 on Wednesday, reaching $3.45. 1,229,368 shares of the stock were exchanged, compared to its average volume of 1,202,390. The company has a debt-to-equity ratio of 0.26, a current ratio of 11.31 and a quick ratio of 11.31. Savara has a one year low of $3.28 and a one year high of $5.70. The stock has a market cap of $567.87 million, a PE ratio of -8.24 and a beta of 1.02. The stock has a 50 day moving average price of $3.96 and a 200 day moving average price of $4.22.

Analyst Ratings Changes

Several analysts have recently weighed in on SVRA shares. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price objective on shares of Savara in a report on Tuesday, October 1st. HC Wainwright cut their price objective on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Evercore ISI restated an “in-line” rating and set a $5.00 target price (down previously from $7.00) on shares of Savara in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.17.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.